This report was first published by Endpoints News. To see the original version, click here
Bristol Myers Squibb is the latest large pharma to tap into the speed and efficiency of drug R&D in China.
The New York drug giant will pay as much as $90 million in upfront and near-term payments, plus up to $1.035 billion in potential future payments, to Harbour BioMed to create new multi-specific antibodies, Harbour said Tuesday night.
您已閱讀21%（429字），剩余79%（1603字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。